Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides.

@article{Okabe2001ClinicalEO,
  title={Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides.},
  author={Reiko Okabe and Kiyoshi Nakatsuka and Masaaki Inaba and Takami Miki and Hiroshi Naka and Hideki Masaki and Atushi Moriguchi and Yoshiki Nishizawa},
  journal={Clinical chemistry},
  year={2001},
  volume={47 8},
  pages={1410-4}
}
BACKGROUND The Elecsys beta-CrossLaps serum assay measures type I collagen degradation fragments (beta-CTx) that contain the beta-isomerized octapeptide EKAHD-beta-GGR. We investigated the analytical performance of the assay and changes in beta-CrossLaps in patients with metabolic bone diseases. METHODS The electrochemiluminescent sandwich immunoassay uses two monoclonal antibodies directed against different regions of the linear EKAHD-beta-GGR. RESULTS beta-CrossLaps (beta-CTx… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…